Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.68 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.68 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.65 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27891419 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2831405 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL27855529 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2835497 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2833540 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2831996 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2831336 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL1871699 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL1411995 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6676953 | 1.00 | GRIK1 (0.68) | GRIK1GRIK2SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0705094-B1 | SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS | CARSON PROD CO (US) | 2000-05-24 | — | — | EP | claimed |
| EP-3273938-B1 | COSMETIC PRODUCT AND CONCENTRATE FOR PRODUCING THE COSMETIC PRODUCT | GCT GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3273938-A1 | COSMETIC PRODUCT AND CONCENTRATE FOR PRODUCING THE COSMETIC PRODUCT | GCT GmbH (DE) | 2018-01-31 | — | — | EP | disclosed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016150417-A1 | COSMETIC PRODUCT AND CONCENTRATE FOR PRODUCING THE COSMETIC PRODUCT | GCT GMBH (DE) | 2016-09-29 | — | — | WO | disclosed |
| US-8889614-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2654665-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2468239-B1 | Encapsulates | PROCTER & GAMBLE INTERNAT OPERATIONS SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2012083906-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20120152268-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2012-06-21 | — | — | US | disclosed |
| WO-2010115578-A2 | NOVEL COMPOUNDS SUITED AS DIESEL SUPPLEMENTS AND DIESEL SUBSTITUTES AND ROUTES FOR THEIR SYNTHESIS | ETH ZURICH (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | GRIK1 4575/4885GRIK2 4394/4885SLC1A2 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.